Pfizer's innovative targeted therapy drug Taizena has been approved in China
白云追月素
发表于 2024-11-5 17:41:29
210
0
0
The reporter learned that Pfizer's innovative drug for treating prostate cancer, Terzena& reg; (TALZENNA®, The generic name: Terazopanib Tosylate Capsules was approved by the National Medical Products Administration (NMPA) on October 29, 2024, in combination with enzalutamide for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult patients with HRR gene mutations. As the only PARP inhibitor approved for mCRPC treatment of HRR gene mutations in China, Taizena& reg; It will help China achieve breakthroughs in precision diagnosis and treatment of prostate cancer, benefiting Chinese prostate cancer patients. (21st Century Business Herald)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Honda accelerates its electrification layout in China, with joint ventures intensively deploying electric vehicles
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- Nvidia expands in China against the trend, attracting talent and adding hundreds of R&D personnel in one year
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Apple is rumored to have preliminary discussions with Tencent and ByteDance to consider embedding their AI models into iPhones sold in China
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
- Sanofi's BTK inhibitor is declared for market in China